Please use this identifier to cite or link to this item:
https://doi.org/10.1080/15384047.2016.1178427
Title: | Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence | Authors: | Abid, Muhammad Bilal De Mel, Sanjay Abid, Muhammad Abbas Tan, Kong Bing Chng, Wee Joo |
Keywords: | Science & Technology Life Sciences & Biomedicine Oncology Autologous stem cell transplantation (ASCT) bortezomib (velcade) bortezomib-induced peripheral neuropathy (BIPN) immunomodulator (IMID) multiple myeloma (MM) proteasome inhibitors (PI) CENTRAL-NERVOUS-SYSTEM STEM-CELL TRANSPLANTATION LONG-TERM SURVIVAL PERIPHERAL NEUROPATHY CHROMOSOMAL-ABNORMALITIES INVOLVEMENT POMALIDOMIDE ASSOCIATION IMPROVEMENT THERAPY |
Issue Date: | 1-Jan-2016 | Publisher: | TAYLOR & FRANCIS INC | Citation: | Abid, Muhammad Bilal, De Mel, Sanjay, Abid, Muhammad Abbas, Tan, Kong Bing, Chng, Wee Joo (2016-01-01). Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence. CANCER BIOLOGY & THERAPY 17 (7) : 723-726. ScholarBank@NUS Repository. https://doi.org/10.1080/15384047.2016.1178427 | Abstract: | Neuropathy is a common adverse effect of bortezomib. Isolated central nervous system (CNS) relapse in MM remains exceedingly rare and carries a dismal prognosis. We present an unusual case of bortezomib related neuropathy masking a CNS relapse of MM. Case presentation: A 57-year-old female was diagnosed with standard-risk MM with clinical and cytogenetic features not typically associated with CNS involvement. She was treated with 4 cycles of bortezomib/cyclophosphamide/dexamethasone (VCD) and achieved a VGPR, after which she underwent an autologous stem cell transplant (ASCT) followed by bortezomib maintenance. Six months after ASCT she developed symptoms suggestive of peripheral neuropathy which was attributed to bortezomib. However the symptoms persisted despite discontinuation of bortezomib. Imaging and cerebrospinal fluid analysis subsequently confirmed a CNS relapse. Discussion: CNS involvement in MM (CNS-MM) is uncommon and is considered an aggressive disease. Recently published literature has reported biomarkers with prognostic potential. However, isolated CNS relapse is even less common; an event which carries a very poor prognosis. Given the heterogeneous neurologic manifestations associated with MM, clinical suspicion may be masked by confounding factors such as bortezomib-based therapy. The disease may further remain incognito if the patient does not exhibit any of the high risk features and biomarkers associated with CNS involvement. Conclusion: In the era of proteasome inhibitor (PtdIns)/immunomodulator (IMID)-based therapy for MM which carries neurologic adverse effects, it is prudent to consider CNS relapse early. This case further highlights the need for more robust biomarkers to predict CNS relapse and use of newer novel agents which demonstrate potential for CNS penetration. | Source Title: | CANCER BIOLOGY & THERAPY | URI: | https://scholarbank.nus.edu.sg/handle/10635/229037 | ISSN: | 15384047 15558576 |
DOI: | 10.1080/15384047.2016.1178427 |
Appears in Collections: | Elements Staff Publications |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma A call for diligence.pdf | Published version | 528.68 kB | Adobe PDF | OPEN | Published | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.